PATENT CLAIM ANALYSIS

Application Number: 15935739
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-08
Patent Classification: ["424", "464000"]

Abstract:
The present disclosure provides orally deliverable pharmaceutical compositions comprising DGLA and to methods of using same to treat a variety of conditions and disorders.

Claim (Index 56):
The pharmaceutical composition of  claim 48 , wherein upon oral administration of multiple daily doses of said composition to a fasted subject over a period of about 2 to about 30 days, each daily dose comprising about 100 mg to about 8000 mg of DGLA, the subject exhibits one or more of the following outcomes:\n (a) a steady state free DGLA plasma level (Cavg) of up to about 2000 ng/ml, up to about 750 ng/ml, or up to about 350 ng/ml; (b) a steady state total DGLA plasma level (Cavg) of up to 250,000 ng/ml, up to 180,000 ng/ml, up to 150,000 ng/ml, up to 125,000 ng/ml or up to 100,000 ng/ml; and/or (c) a ratio of free DGLA plasma to DGLA as measured in skin blister fluid from about 0.2:1 to about 5:1, about 0.5:1 to about 2.5:1 or about 0.6:1 to about 1.5:1.

Metadata:
- Claim Count in Document: 26.0
- Percentile: 90.0
- Lexical Diversity: 1.13636
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14730818', '15661374', '14307195', '15898148', '15898143']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6964445209358835
- 35 USC 102 Novelty (BERT): 0.5569185232663459
- Combined Prediction Score: 0.6824919211689298
- Mean Citation Score: 317.293044
- Max Citation Score: 448.53607
- Similarity Product: 332.47596205163774

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test